You are here

News

2026

Royan: Treating Autism with Donated UC-MSC product Whartocell
Oct 2026   In Iran, the product Whartocell® containing umbilical cord mesenchymal stromal cells (UC-MSC) has market approval for certain diagnoses. A newly-published clinical trial showed that children with autism had significant improvements after a single intrathecal dose of this product.   children with autism received intrathecal injections of umbilical cord MSC as part of a clinical trial. Their responses were measured by both parents surveys (ATEC) as well as tests administered by clinicians (CARS). All of the children displayed very significant improvements after the first intrathecal injection, even though three injections were given at monthly intervals. Two of the children that started the study with mild to moderate autism lost their autism diagnosis.  The UC-MSC given in this study are a product named Whartocell that has received market approval in Iran for certain diagnoses.
image credit: Radiation Affiliates Imaging
Oct 2026   Most obstetricians in the United States perform two routine ultrasounds during uncomplicated, low-risk pregnancies. However, many expectant moms are getting more scans for a variety of reasons. If there are any risk factors in the pregnancy, the ultrasound can switch from a screening tool to a method of monitoring developments. On the other hand, some moms get lots of scans simply because their doctor has access to the technology and likes to use it. Make sure you understand why you are getting scans and if your insurance is covering it.
NEXT Biosciences: Treating Autism with Autologous UC-MSC
Sep 2026   A boy with autism who previously struggled to speak is now a chatterbox. He was the first child treated in a program in South Africa where children receive intrathecal injections of MSCs grown from their own cryopreserved umbilical cord tissue.
Implementing Cord Blood Therapy for Cerebral Palsy in the US
Sep 2026   Clinicians who work with children that have cerebral palsy have identified five theme topics that impact the ability to implement cord blood therapy in more hospitals.
From Bank to Bedside: ReeLabs of India
Aug 2026   ReeLabs of India stores stem cells from six perinatal sources and four adult sources. ReeLabs is also at the forefront of the regenerative medicine revolution in India. They run clinical trials of cell therapies and offer a patented anti-aging treatment.
Delivering the Placenta
Aug 2026   The placenta is destined to be a temporary organ: when its time is up, a cascade of signals tells the mother's body to expel the placenta after birth. Safe delivery of the placenta is essential to prevent excessive bleeding after birth.
AABB 2026 Annual Meeting Registration
Jul 2026   Registration is now open for the AABB 2026 Annual Meeting, to be held Oct. 17-19 in Atlanta, Georgia, USA.
Red Blood Cells for Premature Babies as a product from Cord Blood Banks
Jul 2026   Extremely premature babies require multiple blood transfusions for anemia. But they benefit more from cord blood than adult blood, because it is rich in fetal hemoglobin. This need could be met by processing the red blood cells that cord blood banks routinely discard, turning it into a product for the transfusion of premature babies.
Neonatal cardiac transfusion as a product from cord blood banks
Jul 2026   Neonatal cardiac surgery is one of the largest and most predictable clinical settings in which autologous cord blood can already be incorporated into routine care. When this indication is included, the odds of using cord blood nearly double. Family cord blood banks should make more effort to tell this story and provide this service.
Interview with Rocio Ayala Edgerton of NECC
Jul 2026   Interview with Rocio Ayala Edgerton of New England Cryogenic Center, about their partnership with Kindbody.